Publikationen, an denen er mitarbeitet MARÍA PILAR ESCRIBANO SUBÍAS (28)

2023

  1. A mutation responsible for impaired detection by the Xpert SARS-CoV-2 assay independently emerged in different lineages during the SARS-CoV-2 pandemic

    BMC Microbiology, Vol. 23, Núm. 1

2022

  1. Different performance of three point-of-care SARS-CoV-2 antigen detection devices in symptomatic patients and close asymptomatic contacts: a real-life study

    Clinical Microbiology and Infection, Vol. 28, Núm. 6, pp. 865-870

  2. High incidence of COVID-19 at nursing homes in Madrid, Spain, despite preventive measures

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 3, pp. 288-292

  3. Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission

    Journal of Fungi, Vol. 8, Núm. 3

  4. Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers

    Microbiology Spectrum, Vol. 10, Núm. 1

2021

  1. Inference of active viral replication in cases with sustained positive reverse transcription-PCR results for SARS-CoV-2

    Journal of Clinical Microbiology, Vol. 59, Núm. 2

  2. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

    Mycoses, Vol. 64, Núm. 2, pp. 132-143

2020

  1. Corrigendum to ‘Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect’ [Clinical Microbiology and Infection, Volume 24, (Issue 12) (December 2018) Pages 1343.e1-1343.e4](S1198743X18305214)(10.1016/j.cmi.2018.07.006)

    Clinical Microbiology and Infection

  2. Corrigendum to “Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect” [Clin Microbiol Infect 24 (12) (December 2018) 1343.e1-1343.e4](10.1016/j.cmi.2018.07.006)

    Clinical Microbiology and Infection

  3. Erratum: Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates (PLOS ONE (2017) 12:6 (e0179136) DOI: 10.1371/Journal.pone.0179136)

    PLoS ONE

  4. Erratum: Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect (Clinical Microbiology and Infection (2018) 24(12) (1343.e1–1343.e4), (S1198743X18305214), (10.1016/j.cmi.2018.07.006))

    Clinical Microbiology and Infection

  5. Invasive Scedosporium and Lomentosora infections in the era of antifungal prophylaxis: A 20-year experience from a single centre in Spain

    Mycoses, Vol. 63, Núm. 11, pp. 1195-1202

  6. Outbreak of COVID-19 in a nursing home in Madrid

    Journal of Infection

  7. Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?

    Infectious Diseases and Therapy, Vol. 9, Núm. 1, pp. 137-149

2019

  1. Detection of Echinocandin-Resistant Candida glabrata in Blood Cultures Spiked with Different Percentages of FKS2 Mutants

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 3

  2. Erratum: Growth kinetics in Candida spp.: Differences between species and potential impact on antifungal susceptibility testing as described by the EUCAST (Medical Mycology (2018) DOI: 10.1093/mmy/myy097)

    Medical Mycology

  3. Fatal disseminated infection by Gymnascella hyalinospora in a heart transplant recipient

    Transplant Infectious Disease, Vol. 21, Núm. 5

  4. Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis

    Mycoses, Vol. 62, Núm. 5, pp. 441-449

  5. Increased species-assignment of filamentous fungi using MALDI-TOF MS coupled with a simplified sample processing and an in-house library

    Medical Mycology, Vol. 57, Núm. 1, pp. 63-70

  6. Infectious endocarditis caused by Candida glabrata: Evidence of in vivo development of echinocandin resistance

    Revista Espanola de Quimioterapia